All In Biotech

Drug Trial Radar · NCT06012435

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE SIGVOTATUG VEDOTIN COMPARED WITH DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER (BE6A LUNG-01)

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 762 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

762

Actual

Start

Feb 21, 2024

Primary completion

May 18, 2026

Study completion May 17, 2028

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle. This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • sigvotatug vedotinDrug

    Given into the vein (IV; intravenously) on Day 1 and 15 of a 28-day cycle

  • docetaxelDrug

    75 mg/m\^2 given into the vein (IV; intravenously) on Day 1 of a 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel)Time frame: Approximately 5 years

Locations

331 sites in 25 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology, LLC

    Anchorage, Alaska

  • Providence Medical Foundation

    Fullerton, California

  • Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center

    Fullerton, California

  • Providence St. Jude Medical Center

    Fullerton, California

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California

  • Cancer Blood and Specialty Clinic

    Los Alamitos, California

  • Regulatory Management Only: TRIO-US Central Administration

    Los Angeles, California

  • Drug Management Only: UCLA West Medical Pharmacy Attn: Steven L. Wong, Pharma.D.

    Los Angeles, California

  • Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D.

    Los Angeles, California

  • UCSF Medical Center - Mission Bay

    San Francisco, California

  • Sansum Clinic

    Santa Barbara, California

  • Sansum Clinic

    Solvang, California

  • Rocky Mountain Cancer Centers LLP

    Aurora, Colorado

  • Rocky Mountain Cancer Centers LLP

    Boulder, Colorado

  • Rocky Mountain Cancer Centers LLP

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers LLP

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers LLP

    Denver, Colorado

  • Rocky Mountain Cancer Centers LLP

    Denver, Colorado

  • Rocky Mountain Cancer Centers LLP

    Lakewood, Colorado

  • Rocky Mountain Cancer Centers LLP

    Littleton, Colorado

  • Rocky Mountain Cancer Centers LLP

    Lone Tree, Colorado

  • Rocky Mountain Cancer Centers LLP

    Longmont, Colorado

  • Rocky Mountain Cancer Centers LLP

    Pueblo, Colorado

  • Rocky Mountain Cancer Centers LLP

    Thornton, Colorado

  • Cancer Specialists of North Florida

    Fleming Island, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Cancer Specialists of North Florida

    Jacksonville, Florida

  • Cancer Care Centers of Brevard, Inc.

    Melbourne, Florida

  • Baptist Hospital of Miami

    Miami, Florida

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida

  • Cancer Specialists of North Florida

    Neptune Beach, Florida

  • Cancer Care Centers of Brevard, Inc.

    Palm Bay, Florida

  • Cancer Care Centers of Brevard, Inc.

    Rockledge, Florida

  • Cancer Specialists of North Florida

    Saint Augustine, Florida

  • Illinois Cancer Specialists

    Arlington Heights, Illinois

  • Illinois Cancer Specialists

    Niles, Illinois

  • Maryland Oncology Hematology P.A.

    Annapolis, Maryland

  • Maryland Oncology Hematology P.A.

    Bethesda, Maryland

Showing 40 of 331 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.